Bronchial Carcinoids: From Molecular Background to Treatment Approach.

Unfortunately, the primary endpoint of this trial, PFS per investigator assessment, did not reach statistical significance (median PFS 17.2 month in axitinib arm vs. 12.3 months in place group, HR 0.816, p = 0.169).

also in 111,027 other papers